X

Trial Profile

A retrospective study of effect of dimethyl fumarate on cerebral gray matter in patients with multiple sclerosis

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dimethyl fumarate (Primary)
Indications Multiple sclerosis
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

01 Dec 2016 Results of preliminary analysis, assessing the effect of dimethyl fumarate on cerebral gray matter over one-year (n=28) published in the Neurology and Therapy.
12 Nov 2016 New trial record
17 Sep 2016 Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com